

or a pharmaceutically acceptable salt or prodrug thereof;

provided that when Y⁵ is -O-CH₂-, or -CH₂-O-, then at least one of the following occurs:

- (1) at least one of V^{1a} and V^{1b} is selected from (af), (ag), (ah), (ai), (aj), (ak), (al), (am), (an), (ao), (ap) or (aq); or
- (2) P^{1a} is selected from (be), (bf), (bg), (bh), (bi), (bj), (bk), (bl), (bm), (bn), (bo), (bq) or (br); or
- (3) P^{1b} is selected from (be), (bf), (bg), (bh), (bi), (bj), (bk), (bl), (bm), (bn), (bo), (bp), (bq) or (br).

The disclosure also provides isotopically enriched compounds that are compounds of the disclosure that comprise an enriched isotope at one or more positions in the compound.

In one aspect, there is provided a pharmaceutical composition comprising the compound or pharmaceutically acceptable salt described herein and at least one pharmaceutically acceptable diluent or carrier, or combination thereof.

The present disclosure also provides a pharmaceutical composition comprising a compound of the disclosure or a pharmaceutically acceptable salt or prodrug thereof and at least one pharmaceutically acceptable carrier.

In one aspect, there is provided the compound or pharmaceutically acceptable salt described herein for use in the prophylactic or therapeutic treatment of hepatitis C.


In one ~~aspect~~embodiment, there is provided use of the compound described herein in the manufacture of a medicament for the treatment of hepatitis C.

In one aspect, there is provided the pharmaceutical composition described herein for use in the prophylactic or therapeutic treatment of hepatitis C.

The present disclosure also provides a pharmaceutical composition for use in treating hepatitis C (HCV). In one embodiment the composition comprises at least one additional therapeutic agent for treating HCV. In one embodiment, the therapeutic agent is selected from ribavirin, an NS3 protease inhibitor, a nucleoside or nucleotide inhibitor of HCV NS5B polymerase, an alpha-glucosidase 1 inhibitor, a hepatoprotectant, a non-nucleoside inhibitor of HCV polymerase, or combinations thereof. In one embodiment, the composition further comprises a nucleoside or nucleotide inhibitor of HCV NS5B polymerase. In one embodiment, the nucleoside or nucleotide inhibitor of HCV NS5B polymerase is selected from ribavirin, viramidine, levovirin, a L-nucleoside, or isatoribine.


Claims

1. A compound of formula:



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable diluent or carrier, or combination thereof.
3. The pharmaceutical composition of claim 2, formulated for oral administration.
4. The pharmaceutical composition of claim 2, formulated in tablet form.
5. The compound of claim 1 for use in the prophylactic or therapeutic treatment of hepatitis C.
6. Use of the compound of claim 1 in the manufacture of a medicament for the treatment of hepatitis C.
7. The pharmaceutical composition of claim 2 for use in the prophylactic or therapeutic treatment of hepatitis C.
8. A compound of formula:



9. A pharmaceutical composition comprising the compound of claim 8 and a pharmaceutically acceptable diluent or carrier, or combination thereof.
10. The pharmaceutical composition of claim 9, formulated for oral administration.
11. The pharmaceutical composition of claim 9, formulated in tablet form.


~~12. The compound of claim 8 for use in the prophylactic or therapeutic treatment of hepatitis C.~~

13. Use of the compound of claim 8 in the manufacture of a medicament for the treatment of hepatitis C.

14. The pharmaceutical composition of claim 9 for use in the prophylactic or therapeutic treatment of hepatitis C.


Claims

1. A compound of formula:



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of claim 1 and at least one pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2, formulated for oral administration.
4. The pharmaceutical composition of claim 2, formulated in tablet form.
5. The compound or pharmaceutically acceptable salt of claim 1 for use in the prophylactic or therapeutic treatment of hepatitis C.
6. A compound of formula:



7. The pharmaceutical composition of claim 2 for use in the prophylactic or therapeutic treatment of hepatitis C.